Huntington’s disease – Discover Pharma

Welcome to Discover Pharma! Today is : September 17, 2026

Huntington’s disease

Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development
SKY-0515 shows 1.59-point cUHDRS difference in Huntington’s disease study
Skyhawk Therapeutics’ investigational oral treatment SKY-0515 showed a 1.59-point difference [...]
September 17, 2026
Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Skyhawk expands global Huntington’s disease trial following positive Phase 1/2 data
Skyhawk Therapeutics has expanded its global pivotal Phase 2/3 clinical [...]
July 14, 2026
Advanced Therapies,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
Skyhawk reports encouraging 12-month Huntington’s disease data for SKY-0515
Skyhawk Therapeutics has reported encouraging 12-month results from its ongoing [...]
June 6, 2026
Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
Skyhawk Therapeutics reports positive nine-month interim results for SKY-0515 in Huntington’s disease
Skyhawk Therapeutics has reported positive nine-month interim results from its [...]
May 5, 2026
Advanced Therapies,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
Gene therapy AMT-130 slows Huntington’s disease progression in early trial
A gene therapy developed by uniQure appears to slow progression [...]
May 5, 2026
Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
SOM Biotech secures EMA orphan designation opinion for Huntington’s drug SOM3355
Barcelona-based biotech advances Huntington’s programme as EMA backs orphan designation, [...]
May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.